Hyponatraemia (of grade III-IV severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events) has been found to occur in up to 8% of patients treated with both BRAF and MEK inhibitors for non-small cell lung cancer with the risk of hyponatraemia increasing with dual inhibition treatment [16]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.